This inventor holds 2 USPTO granted patents. Top assignee: Sanofi-Synthelabo. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Attila Kis-Tamás - Innovator in Chemical Processes
Introduction
Attila Kis-Tamás is a distinguished inventor based in Budapest, Hungary, known for his significant contributions to the field of chemistry. With a total of two patents to his name, his work revolves around innovative processes that have applications in medicinal chemistry.
Latest Patents
His latest patents include groundbreaking methods for the preparation of 1,3-diaza-spiro (4.4) non-1-en-4-one derivatives and 1-cyano-1-acylamino-cyclopentane intermediates. These innovative processes involve the synthesis of compounds that are valuable in the production of angiotensin II antagonists. The methodologies he developed encompass various chemical transformations, including reactions with halogenated compounds, anhydrides, and the use of oxidizing agents under alkaline conditions to yield complex structures essential for pharmaceutical applications.
Career Highlights
Attila currently works at Sanofi-Synthelabo, a prominent global player in the pharmaceutical industry. His expertise in developing chemical processes contributes to the advancement of drug development and the creation of new therapeutic agents.
Collaborations
Throughout his career, Attila has worked alongside talented colleagues such as Csaba Huszár and Attila Németh. Their collaborative efforts have played a significant role in the successful development of innovative chemical processes and have strengthened Sanofi-Synthelabo's position in the competitive pharmaceutical landscape.
Conclusion
Attila Kis-Tamás stands out as a dedicated inventor whose work exemplifies innovation in chemical processes. His patents not only enhance the capabilities of pharmaceutical research but also pave the way for the advancement of therapeutic solutions. The impact of his work will undoubtedly continue to influence the field for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
